EC Council Directive 65/65/EEC 'On the
approximation of provisions laid down by law, regulation or administrative action relating
to proprietary medicinal products.'
2.
EC Council Directive 75/318/EEC 'On the
approximation of laws of Member States relating to analytical, pharmacotoxicological and
clinical standards and protocols in respect of the testing of proprietary medicinal
products.'
3.
EC Council Directive 87/22/EEC 'On the
approximation of national measures relating to the placing on the market of
high-technology medicinal products, particularly those derived from
biotechnology.'
4.
Chernick WS & Barbero
GJComposition of tracheobronchial secretions
in cystic fibrosis of the pancreas and bronchiectasis.
Pediatrics1959; 24:
739-45.
5.
Potter J., Matthews LW,
Lemm
J. & Spector S.The composition of
pulmonary secretions from patients with and without cystic fibrosis.
American Journal of Disease in Childhood1960;
100: 493-5.
6.
Matthews LW, Spector S.,
Lemm
J. & Potter JLThe over-all
chemical composition of pulmonary secretions from patients with cystic fibrosis,
bronchiectasis, and laryngectomy. American Review of Respiratory
Disease1963; 88(2):
199-204.
7.
Colledge WH, Ratcliff R.,
Foster
D., Williamson R. & Evans
MJCystic fibrosis mouse with intestinal
obstruction. Lancet1992;
340: 680.
8.
Dorin JR, Dickinson P.,
Alton
Ewfw, Smith SN, Geddes DM,
Stevenson
BJ, et al. Cystic fibrosis in the mouse by
targeted insertional mutagenesis .
Nature1992; 359:
211-5.
9.
Snouwaert JN , Brigman KK,
Latour
AM, Malouf NN, Boucher RC,
Smithies
O., et al. An animal model for cystic
fibrosis made by gene targeting.
Science1992; 257:
1083-8.
10.
Maas K., Shak S. &
Smith
ALRecombinant human DNase I greatly
potentiates the bactericidal activity of tobramycin in sputum.
Clinical Research1992 ;
40(2): 384a.
11.
Raabe OGDeposition and clearance of
inhaled aerosols. In: Witschi H, Nettesheim P, eds.
Mechanisms in Respiratory Toxicology. Florida: CRC
Press, Inc., 1982; 1:
27-76.
12.
Mordenti J., Chen SA,
Moore
JA, Ferraiolo BL & Green
JDInterspecies scaling of clearance and
volume of distribution data for five therapeutic proteins.
Pharmaceutical Research1991;
8(11):
1351-9.
13.
Mejean C., Roustan C. &
Benyamin
Y.Anti-actin antibodies: Detection and
quantitation of total and skeletal muscle actin in human plasma using a competitive
ELISA. Journal of Immunological
Methods1987; 99:
129-35.
14.
Emerson DL, Arnaud P. &
Galbraith
RMEvidence of increased Gc:actin complexes
in pregnant serum: a possible result of trophoblast embolism.
American Journal of Reproductive Immunology1983;
4: 185-9.
15.
Lee WM, Emerson DL,
Young
WO, Goldschmidt-Clermont PJ, Jollow DJ &
Galbraith
RMDiminished serum Gc (vitamin D-binding
protein) levels and increased Gc:G-actin complexes in a hamster model of fulminant
hepatic necrosis. Hepatology1987;
7(5):
825-30.
16.
Lee WM, Emerson DL,
Werner
Pam, Arnaud P., Goldschmidt-Clermont
P. & Galbraith RMDecreased serum
group-specific component protein levels and complexes with actin in fulminant hepatic
necrosis. Hepatology1985;
5(2):
271-5.
17.
Johnson AJ, Goger PR &
Tillet
WSThe intravenous injection of bovine
crystalline pancreatic desoxyribonuclease into patients. Journal
of Clinical Investigation1954; 33:
1670-85.
18.
Lazarides E. & Lindberg
U.Actin is the naturally occurring inhibitor
of deoxyribonuclease IProceedings of the National Academy of
Sciences USA1974; 71(12):
4742-6.
19.
Pinder JC & Gratzer
WBInvestigation of the
actin-deoxyribonuclease I interaction using a pyrene-conjugated actin
derivative. Biochemistry1982;
21: 4886-90.
20.
Sinicropi D. & Chen
ABELISA for rhDNase in rat serum. Assay
Qualification Summary No. S 92-017-0230; Report Date 1-15-90 (See Appendix A: Assay
Qualification Summaries)
21.
Sinicropi D. & Chen
ABELISA for rhDNase in monkey and human
serum. Assay Qualification Summary No. S 92-018-0230; Report Date 11-16-89 (See
Appendix A: Assay Qualification Summaries)
22.
D'Arcy PF & Harron DWG, eds. Session
III(ii): workshop: safety. Proceedings of the First International Conference on
Harmonisation -Brussels1991,
International Federation of Pharmaceutical Manufacturers Association; Antrim, Northern
Ireland: 1992; 295-319.
23.
Committee for Proprietary Medicinal Products, Ad Hoc Working Party on
Biotechnology/ Pharmacy, Working Party on Safety of
Medicines.Notes to Applicants for Marketing
Authorizations on the Pre-Clinical Biological Safety Testing of Medicinal Products
Derived from Biotechnology (and Comparable Products Derived from Chemical
Synthesis) . (III/407/87) September 1988:
73-88.
24.
Weissinger J.Nonclinical
pharmacologic and toxicologic considerations for evaluating biologic
products. Regulatory Toxicology and
Pharmacology1989; 10:
255-63.
25.
Donohoe J.Human therapeutic
and diagnostic products: preclinical aspects. Australian Journal
of Biotechnology1989; 3(4):
309-10.
26.
Sundwall A, Ekman L,
Johansson
H-E, Sjoberg B & Sjoholm I , eds.
Preclinical evaluation of peptides and recombinant proteins: workshop
excerpts; 1990 May 7-8; Stockholm,
Sweden, Skogs Grafiska AB, Sweden, 1990;
117-28.
27.
Green JDCan conventional
toxicity testing deal with biotechnology products?
Proceedings of the Australasian Society of Clinical and Experimental
Pharmacologists and Toxicologists-Workshop; 1991;
Canberra, Australia, 1992;
18-30.
28.
Greischel A., Tanswell P.,
Busch
U. & Schumacher
K.Pharmacokinetics and biodisposition of
recombinant human interferon-α2C in rat and marmoset. Drug
Research1988; 38(II):
1539-43.
29.
Regoeczi E.Iodine-labeled plasma
proteins. In: Witschi
H & Nettesheim P, eds. Mechanisms in
Respiratory Toxicology, Vol II, Part B. Florida:
CRC Press, Inc., 1987:
43-71.
30.
Sodoyez JC, Sodoyez-Goffaux FR
& Moris
YM125I-Insulin: kinetics of interaction with
its receptors and rate of degradation in vivo. American
Physiological Society1980 ;
2:E3-11.
31.
Guyton ACAnalysis of
respiratory patterns in laboratory animals. American Journal of
Physiology1947; 150:
78-83.
32.
Raabe OGDeposition and clearance of
inhaled aerosols. In: Witschi H & Nettesheim P, eds.
Mechanisms in Respiratory Toxicology. Florida: CRC
Press, Inc., 1982; 1:
27-76.
33.
Raab OG, Yeh H-C.,
Newton
GJ, Phalen RF & Velasquez
DJDeposition of inhaled monodisperse aerosols in
small rodents. In: Walton
WH, ed. Inhaled Particles IV, part 1.
Oxford: Pergamon Press,
1977: 3-21.
34.
Schlesinger RBComparative
deposition of inhaled aerosols in experimental animals and humans: A
review: Journal of Toxicology and Environmental
Health1985; 15:
197-214.
35.
Thurmond LM & Dean
JHImmunological responses following inhalation
exposure to chemical hazards . In: Gardner DE, Crapo JD &
Massaro
EJ, eds. Toxicology of the Lung.
Raven Press: New York,
1988; 375-406.
36.
Haley PJ & Bice
DEImmune reactions in the pulmonary
system. In: Gardner
DE, Crapo JD & Massaro EJ, eds.
Toxicology of the Lung. Raven Press:
New York, 1988;
407-26.
37.
Bice DE, Salvaggio J. &
Hoffman
E.Passive transfer of experimental
hypersensitivity pneumonitis with lymphoid cells in the rabbit.
Journal of Allergy and Clinical Immunology1976;
58(2):
250-62.
38.
Barboriak JJ , Knoblock HW,
Hensley
GT, Gombas OF & Fink
JNAnimal model of sensitization by
inhalation . Clinical and Experimental
Immunology1976 ; 24:
542-5.
39.
Butler JE, Swanson PA,
Richerson
HB, Ratajczak HV, Richards DW &
Suelzer
MTThe local and systemic IgA and IgG
antibody responses of rabbits to a soluble inhaled antigen.
American Review of Respiratory Diseases1982;
126: 80-5.
40.
Konishi K., Satoh S.,
Ida
S. & Takishima T.A rabbit model
for hypersensitivity pneumonitis. Tohoku Journal of
ExperimentalMedicine1984;
142: 381-9.
41.
Hensley GT, Fink JN &
Barboriak
JJHypersensitivity pneumonitis in the
monkey. Archives ofPathology1974;
97: 33-8.
42.
Mason MJ, Gillett NA &
Bice
DEComparison of systemic and local immune
responses after multiple pulmonary antigen exposures. Regional
Immunology1989 ; 2(3):
149-57.
Larsen GLHypersensitivity
lung disease. Annual Reviews in
Immunology1985; 3:
59-85.
45.
Moore VL & Fink
JNImmunologic studies in hypersensitivity
pneumonitis-quantitative precipitins and complement-fixing antibodies in symptomatic and
asymptomatic pigeon breeders. Journal of Laboratory and
ClinicalMedicine1975;
85(4):
540-5.
46.
Parratt D., Nielsen KH,
Boyd
G. & White RGThe quantitation of
antibody in Farmer's lung syndrome using a radioimmunoassay .
Clinical and Experimental Immunology1975 ;
20: 217-25.
47.
Gordon T. & Amdur
MOResponses of the respiratory system to toxic
agents. In: Amdur
MO, Doull J & Klaassen CD, eds.
Casarett and Doull's Toxicology: The Basic Science of Poisons,
4th edition. New York:
Pergamon Press , 1991;
383-406.
48.
Chen AB, Baker DL &
Ferraiolo
B.Points to consider in correlating bioassays and
immunoassays in the quantitation of peptides and proteins. In: Garzone PD,
Colburn
WA & Mokotoff M, eds. Pharmacokinetics
and Pharmacodynamics Vol. 3, Peptides, Peptoids and Proteins.
Ohio: Harvey Whitney
Books, 1991;
53-71.
49.
Folle GA, Johannes C. &
Obe
G.Induction of chromosomal aberrations by
DNase I. International Journal of Radiation
Biology1991; 59(6):
1371-8.
50.
Raabe OG, Yeh H-C.,
Newton
GJ, Phalen RF & Velasquez
DJDeposition of inhaled monodisperse aerosols in
small rodents. In: Walton
WH, ed. Inhaled Particles IV, part 1.
Oxford: Pergamon Press,
1977: 3-21.
51.
Schlesinger RBComparative
deposition of inhaled aerosols in experimental animals and humans. A
reviewJournal of Toxicology and Environmental
Health1985; 15:
197-214.
